Cancer Cell Metastasis Prevention: Restoring Order
- A new study led by Weill Cornell Medicine suggests a surprising approach to combatting triple negative breast cancer (TNBC), one of the most aggressive and challenging-to-treat forms of...
- Metastasis - the spread of cancer cells to distant parts of the body - is the primary reason for the poor survival rates associated with TNBC.
- "Metastasis is the main reason patients with triple negative breast cancer face poor survival odds," said senior author Dr.
Okay,here’s a draft article based on the provided text,adhering to all the specified requirements. It’s designed to be informative, authoritative, and Google News-friendly. I’ve included all the required components and formatting.
“`html
blocking EZH2 Enzyme Shows Promise in Stopping Aggressive Triple negative Breast Cancer Spread
A new study led by Weill Cornell Medicine suggests a surprising approach to combatting triple negative breast cancer (TNBC), one of the most aggressive and challenging-to-treat forms of the disease. Researchers have discovered that an enzyme called EZH2 plays a critical role in driving TNBC cell division and subsequent spread to other organs. preclinical findings indicate that drugs blocking EZH2 could restore normal cell division and prevent metastasis.
The Challenge of Triple Negative Breast Cancer
Metastasis – the spread of cancer cells to distant parts of the body – is the primary reason for the poor survival rates associated with TNBC. Unlike other breast cancers, TNBC lacks the presence of estrogen and progesterone receptors and doesn’t overexpress the HER2 protein, limiting treatment options. This makes it especially challenging to treat.
“Metastasis is the main reason patients with triple negative breast cancer face poor survival odds,” said senior author Dr. Vivek Mittal, Ford-Isom Research Professor of Cardiothoracic Surgery and member of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine. “Our study suggests a new therapeutic approach to block metastasis before it starts and help patients overcome this deadly cancer.”
Dr. Vivek Mittal
